- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2193-6536
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders ; volume:8 ; number:2 ; day:12 ; month:12 ; year:2019 ; pages:83-94 ; date:12.2019
Neurology and Therapy ; 8, Heft 2 (12.12.2019), 83-94, 12.2019
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40120-019-00168-1
- URN
-
urn:nbn:de:101:1-2020040521310529182840
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ashton, Nicholas J.
- Ide, Mark
- Zetterberg, Henrik
- Blennow, Kaj
- SpringerLink (Online service)
Ähnliche Objekte (12)
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
Blood-based molecular biomarkers for Alzheimer’s disease
Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study
No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
Blood-based molecular biomarkers for Alzheimer’s disease
Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study
No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
Blood-based molecular biomarkers for Alzheimer’s disease
Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study
No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease